Discovery of 3,5-disubstituted-1H-pyrrolo[2,3-b]pyridines as potent inhibitors of the insulin-like growth factor-1 receptor (IGF-1R) tyrosine kinase

Bioorganic and Medicinal Chemistry Letters

Volumn 19, Issue 11, 2009, Pages 3136-3140

  Patnaik, Samarjit ^a   Stevens, Kirk L ^a   Gerding, Roseanne ^a   Deanda, Felix ^a   Shotwell, J Brad ^a   Tang, Jun ^a   Hamajima, Toshihiro ^b   Nakamura, Hiroko ^b   Leesnitzer, M Anthony ^a   Hassell, Anne M ^a   Shewchuck, Lisa M ^a   Kumar, Rakesh ^a   Lei, Huangshu ^a   Chamberlain, Stanley D ^a  

^a GLAXOSMITHKLINE   (United States)

^b Development and Medical Affairs Division   (Japan)

Author keywords

IGF 1R; IGF IR; Kinase inhibitor; Pyrrolopyridine

Indexed keywords

3,4 DISUBSTITUTED 1H PYRROLO[2,3 BETA]PYRIDINE; PROTEIN TYROSINE KINASE INHIBITOR; PYRIDINE DERIVATIVE; PYRROLOPYRIDINE INHIBITOR; SOMATOMEDIN C RECEPTOR; UNCLASSIFIED DRUG;

ARTICLE; CELL ASSAY; DRUG POTENCY; DRUG SYNTHESIS; ENZYME ASSAY; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS;

DRUG DESIGN; PROTEIN KINASE INHIBITORS; PYRIDINES; PYRROLES; RECEPTOR, IGF TYPE 1; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 65149102076     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2008.12.110     Document Type: Article

References (21)

1. Pollack M.N., Schernhammer E.S., and Hankinson S.E. Nat. Rev. Cancer 4 (2004) 505
2. Ryan P.D., and Goss P.E. Oncologist 13 (2008) 16 (and references therein)
3. Paz K., and Hadari Y.R. Comb. Chem. High Throughput Screen. 11 (2008) 62
4. García-Echeverría C., Pearson M.A., Marti A., Meyer T., Mestan J., Zimmermann J., Gao J., Brueggen J., Capraro H.G., Cozens R., Evans D.B., Fabbro D., Furet P., Porta D.G., Liebetanz J., Martiny-Baron G., Ruetz S., and Hofmann F. Cancer Cell 5 (2004) 231
5. Mulvihill M.J., Ji Q.S., Coate H.R., Cooke A., Dong H., Feng L., Foreman K., Rosenfeld-Franklin M., Honda A., Mak G., Mulvihill K.M., Nigro A.I., O'Connor M., Pirrit C., Steinig A.G., Siu K., Stolz K.M., Sun Y., Tavares P.A., Yao Y., and Gibson N.W. Bioorg. Med. Chem. 16 (2008) 1359-1375
6. Ji Q.S., Mulvihill M.J., Rosenfeld-Franklin M., Cooke A., Feng L., Mak G., O'Connor M., Yao Y., Pirritt C., Buck E., Eyzaguirre A., Arnold L.D., Gibson N.W., and Pachter J.A. Mol. Cancer Ther. 6 (2007) 2158-2167
7. Mulvihill M.J., Ji Q.S., Werner D., Beck P., Cesario C., Cooke A., Cox M., Crew A., Dong H., Feng L., Foreman K.W., Mak G., Nigro A., O'Connor M., Saroglou L., Stolz K.M., Sujka I., Volk B., Weng Q., and Wilkes R. Bioorg. Med. Chem. Lett. 17 (2007) 1091
8. Saulnier M.G., Frennesson D.B., Wittman M.D., Zimmermann K., Velaparthi U., Langley D.R., Struzynski C., Sang X., Carboni J., Li A., Greer A., Yang Z., Balimane P., Gottardis M., Attar R., and Vyas D. Bioorg. Med. Chem. Lett. 18 (2008) 1702
9. Velaparthi U., Liu P., Balasubramanian B., Carboni J., Attar R., Gottardis M., Li A., Greer A., Zoeckler M., Wittman M.D., and Vyas D. Bioorg. Med. Chem. Lett. 17 (2007) 3072
10. Velaparthi U., Wittman M., Liu P., Stoffan K., Zimmermann K., Sang X., Carboni J., Li A., Attar R., Gottardis M., Greer A., Chang C.Y., Jacobsen B.L., Sack J.S., Sun Y., Langley D.R., Balasubramanian B., and Vyas D. Bioorg. Med. Chem. Lett. 17 (2007) 2317
11. Bell I.M., Stirdivant S.M., Ahern J., Culberson J.C., Darke P.L., Dinsmore C.J., Drakas R.A., Gallicchio S.N., Graham S.L., Heimbrook D.C., Hall D.L., Hua J., Kett N.R., Kim A.S., Kornienko M., Kuo L.C., Munshi S.K., Quigley A.G., Reid J.C., Trotter B.W., Waxman L.H., Williams T.M., and Zartman C.B. Biochemistry 44 (2005) 9430
12. 2, 0.1 mg/ml BSA, at room temperature. Compounds, titrated in DMSO, were evaluated at eleven concentrations ranging from 50 μM to 0.2 nM. Reactions were incubated for 1 h at room temperature and were stopped by a 5-μl addition of EDTA (to 33 mM). A further addition of 5 μl detection reagents (for final 7 nM Streptavidin-APC (Perkin-Elmer #CR130-150), 1 nM Europium-labeled anti-phosphotyrosine monoclonal antibody (Perkin-Elmer #AD0067), added in reaction buffer (without DTT), was required for signal generation. After 30 minutes, signal was read on Perkin-Elmer Viewlux microplate imager or Wallac Victor fluorometer as subtracted from all samples for background).
13. Arnold, W. D.; Bounaud, P.; Gosberg, A.; Li, Z.; McDonald, I.; Steensma, R. W.; Wilson, M. E. US2007043068-A1, 2007.
14. Arnold, W. D.; Bounaud, P.; Gosberg, A.; Li, Z.; McDonald, I.; Steensma, R. W.; Wilson, M. E. WO2006015123-A1, 2006.
15. Graczyk, P.; Palmer, V.; Khan, A. WO Patent 2004101565-A2, A3, 2004.
16. For a recent discussion of crystal structures of 1H-pyrrolo[2,3-b]pyridines bound to protein kinases, see:. Tsai J., et al. Proc. Natl. Acad. Sci. U.S.A. 105 (2008) 3041
17. 50) was determined by 4 parameter fit of data using XLfit (value of no cell control was subtracted from all samples for background).
18. The cellular potencies of 19 and 21, reported in Table 1, were not determined.
19. factor of 20% at 2.6 Å using REFMAC. Crystallographic data for the structure in Figure 1 have been deposited at PDB:3ETA.
20. For kinase ATP binding pocket nomenclature, see:. Vulpetti A., and Bosotti R. Il Farmaco 59 (2004) 759
21. Compound 23 inhibited cellular proliferation in a COLO205 cell line with EC50 at 274 nM (average of 4 measurements).